|
The Management Team BioHybrid Technologies was founded in 1985 by our CEO, John L. Hayes, and the late Dr. William Chick. The goal of BioHybrid's Artificial Organ technology is to make cell transplantation of both human and animal cells a reality, without the use of adjunctive immunosuppressive therapy. Our first target is the transplantation of xenogeneic islets for the treatment of diabetes. The BioHybrid Artificial Pancreas involves the isolation and purification of islet cells, encapsulation of these islets in microreactors, which shield or protect them from the body's immune system, and injection of these microreactors into the peritoneum of the patient. Sensor Technologies was founded in 1988 by our CEO, John L. Hayes, and the late Dr. William Chick. Sensor Technologies specializes in fluorescence-based assay systems. Sensor's ONE SystemTM provides the first easy-to-use and user friendly Fluorescence Correlation Spectroscopy platform. Sensor's patented glucose sensing technology represents a fundamental advance in glucose monitoring. A tiny implant containing a fluorescent glucose-sensitive chemistry is placed beneath the surface of the skin in an outpatient procedure. The fluorescence signal from this implant is read across the skin to determine the patient’s glucose concentration. Sensor's technology will allow long-term continuous glucose monitoring and, for the first time, raises the real possibility of closed-loop insulin delivery
Job Opening: Biophysics Research Associate We have an opening for a biophysics research associate. Responsibilities include:
Requirements: To apply, email Lori Bower with your CV. |
SS |
|||||
|
|||||||
© 2007 Sensor Technologies LLC |
|||||||